CM
RVNC

Castleark Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Castleark Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-125,727
Closed -$3.18M – 322
2023
Q2 		$3.18M Buy
125,727
+23,140
+23% +$721K 0.14% 148
2023
Q1 		$3.3M Buy
102,587
+44,220
+76% +$1.38M 0.16% 135
2022
Q4 		$1.08M Sell
58,367
-79,980
-58% -$1.83M 0.06% 191
2022
Q3 		$3.73M Buy
138,347
+9,034
+7% +$183K 0.21% 122
2022
Q2 		$1.79M Buy
+129,313
New +$1.99M 0.1% 169

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Castleark Management's RVNC Position: Q3 2023 in Review

Castleark Management sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 125,727 shares — an estimated $3.18M sold.

Castleark Management first reported a position in RVNC in Q2 2022 and held it in 5 quarters. The position peaked at $3.73M in Q3 2022. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • Castleark Management reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • Castleark Management sold 125,727 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $3.18M.
  • Castleark Management first reported a position in Revance Therapeutics, Inc. in Q2 2022 and held it in 5 quarters.
  • Castleark Management's Revance Therapeutics, Inc. position peaked at $3.73M in Q3 2022.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Castleark Management's 13F filing for Q3 2023, filed 15 Nov 2023.